Breast cancers in monoallelic MUTYH germline mutation carriers have clinicopathological features overlapping with those in BRCA1 germline mutation carriers

被引:3
|
作者
Keske, Aysenur [1 ]
Weisman, Paul [1 ]
Ospina-Romero, Monica [1 ]
Raut, Prachi [1 ]
Smith-Simmer, Kelcy [2 ,3 ]
Zakas, Anna L. [2 ,3 ]
Flynn, Christopher [1 ]
Xu, Jin [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA
[2] Univ Wisconsin, Master Genet Counselor Studies, Acad Affairs, Sch Med & Publ Hlth, Madison, WI USA
[3] Univ Wisconsin, Oncol Genet, UW Hlth, Carbone Canc Ctr, Madison, WI USA
关键词
Hereditary breast cancer; MUTYH; Breast cancer with divergent grade/biomarker status; COLORECTAL-CANCER; RISK;
D O I
10.1007/s10549-023-07173-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Breast cancer patients referred to genetic counseling often undergo genetic testing with broad panels that include both breast cancer susceptibility genes as well as genes more specific for extramammary sites. As a result, patients are often incidentally found to have germline mutations in genes that are not necessarily related to breast cancer risk. One such gene is MUTYH. To understand the role MUTYH may play in breast cancer, the clinicopathological features of patients with monoallelic MUTYH germline mutation and breast cancer were examined.Methods The clinicopathological characteristics of the breast cancers from patients with monoallelic MUTYH mutation were compared to breast cancer patients with other germline mutations in known breast cancer susceptibility genes, including ATM, BRCA1/2, CHEK2, and PALB2. The breast cancer patients who received genetic counseling but tested negative for the aforementioned gene mutations were used as a control group.Results Histologic characteristics of the breast cancers arising in monoallelic MUTYH mutation carriers had significantly larger tumor size, higher tumor grade, and more high-risk biomarker profiles (i.e., Her2-positive and triple-negative) than breast cancer patients with susceptibility genes, except for BRCA1. MUTYH mutation carriers also showed a trend of more frequent intratumoral divergency in terms of tumor grade and biomarker profiles.Conclusion Although germline monoallelic MUTYH mutation is not thought to confer a meaningfully increased risk of breast cancer development, it may contribute to pathological aggressiveness and diversity of breast cancers when they sporadically arise in MUTYH carriers.
引用
收藏
页码:151 / 158
页数:8
相关论文
共 50 条
  • [41] Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
    Nadine Tung
    Yihong Wang
    Laura C Collins
    Jennifer Kaplan
    Hailun Li
    Rebecca Gelman
    Amy H Comander
    Bridget Gallagher
    Katharina Fetten
    Karen Krag
    Kathryn A Stoeckert
    Robert D Legare
    Dennis Sgroi
    Paula D Ryan
    Judy E Garber
    Stuart J Schnitt
    Breast Cancer Research, 12
  • [42] AURKA and breast cancer in BRCA1/2 mutation carriers
    Bodvarsdottir, Sigridur K.
    Vidarsdottir, Linda
    Eyfjord, Jorunn E.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (11) : 2517 - 2517
  • [43] Survival in Norwegian BRCA1 mutation carriers with breast cancer
    Anne Irene Hagen
    Steinar Tretli
    Lovise Mæhle
    Jaran Apold
    Nina Vedå
    Pål Møller
    Hereditary Cancer in Clinical Practice, 7
  • [44] Are Endometrial Cancers Arising in BRCA1/BRCA2 Germline Mutations Carriers True BRCA1/BRCA2 Cancers?
    Paula, Arnaud Da Cruz
    Smith, Evan
    Cadoo, Karen
    Abu-Rustum, Nadeem
    Pei, Xin
    Riaz, Nadeem
    Robson, Mark
    Reis-Filho, Jorge
    Mandelker, Diana
    Weigelt, Britta
    MODERN PATHOLOGY, 2019, 32
  • [45] Are Endometrial Cancers Arising in BRCA1/BRCA2 Germline Mutations Carriers True BRCA1/BRCA2 Cancers?
    Paula, Arnaud Da Cruz
    Smith, Evan
    Cadoo, Karen
    Abu-Rustum, Nadeem
    Pei, Xin
    Riaz, Nadeem
    Robson, Mark
    Reis-Filho, Jorge
    Mandelker, Diana
    Weigelt, Britta
    LABORATORY INVESTIGATION, 2019, 99
  • [46] Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers
    McCrorie, Alan D.
    Ashfield, Susannah
    Begley, Aislinn
    Mcilmunn, Colin
    Morrison, Patrick J.
    Boyd, Clinton
    Eccles, Bryony
    Greville-Heygate, Stephanie
    Copson, Ellen R.
    Cutress, Ramsey, I
    Eccles, Diana M.
    Savage, Kienan, I
    McIntosh, Stuart A.
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2020, 6 (02): : 146 - 153
  • [47] Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers
    McCrorie, Alan D.
    Ashfield, Susannah
    McIlmunn, Colin
    Morrison, Patrick J.
    Boyd, Clinton
    McIntosh, Stuart A.
    Savage, Kienan I.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 568 - 569
  • [48] MutYH mutation carriers have increased breast cancer risk
    Rennert, Gad
    Lejbkowicz, Flavio
    Cohen, Ilana
    Pinchev, Mila
    Rennert, Hedy S.
    Barnett-Griness, Ofra
    CANCER, 2012, 118 (08) : 1989 - 1993
  • [49] Estrogen Rececptor (ER)-Positive Breast Cancers in BRCA1 Mutation Carriers: Mutation-Related or Sporadic?
    Kaplan, J.
    Schnitt, S.
    Collins, L.
    Wang, Y.
    Garber, J.
    Tung, N.
    CANCER RESEARCH, 2009, 69 (24) : 819S - 819S
  • [50] Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer
    Halpern, Naama
    Sonnenblick, Amir
    Uziely, Beatrice
    Divinsky, Luba
    Goldberg, Yael
    Hamburger, Tamar
    Peretz, Tamar
    Kadouri, Luna
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (09) : 2145 - 2149